Stay updated on Pembrolizumab in MM Residual Disease Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in MM Residual Disease Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in MM Residual Disease Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    Revision: v3.4.3 was published, replacing the previous v3.4.2.
    Difference
    0.1%
    Check dated 2026-03-10T14:40:34.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    Added related topics: Multiple myeloma and MedlinePlus Genetics to the page.
    Difference
    0.2%
    Check dated 2026-02-24T09:07:56.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Revision: v3.4.2 updated from v3.4.1; no study content or functionality changes are visible. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-17T03:08:07.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    Revision: v3.4.1 has been added to the page. Older non-core revision notes (v3.4.0) and non-essential items such as the 'Multiple myeloma' topic and related topics, plus the funding-status notice, were removed.
    Difference
    0.6%
    Check dated 2026-02-09T22:21:33.000Z thumbnail image
  6. Check
    43 days ago
    Change Detected
    Summary
    A site-wide funding notice about government operations and links to related topics (Multiple Myeloma and MedlinePlus Genetics) were added to the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.6%
    Check dated 2026-02-02T21:11:49.000Z thumbnail image
  7. Check
    49 days ago
    Change Detected
    Summary
    The changes are minor UI and metadata adjustments on the study page, including adding 'Show glossary', 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0', and removing 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-26T22:18:10.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in MM Residual Disease Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in MM Residual Disease Clinical Trial page.